UNSPSC 51172121: Darifenacin or darifenacin hydrobromide

This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formulas C28H30N2O2 and C28H30N2O2.BrH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers APG9819VLM and CR02EYQ8GV, the base compound being chemically known as (s)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide but generally known as darifenacin, which bears US NIH Compound Identifier 72054.

UNSPSC 51172121 Darifenacin or darifenacin hydrobromide is a Commodity code that represents a specific pharmaceutical active ingredient used in medications for overactive bladder treatment. State and local government procurement under this code occurs primarily through pharmacy benefit programs, cooperative purchasing alliances, and correctional health services that source pharmaceuticals for their populations. The issuing bodies include state health and human services commissions, cooperative purchasing organizations spanning multiple states and localities, and county correctional departments. Recent solicitations show darifenacin products are procured as part of broader generic pharmaceutical supply contracts rather than as standalone line items, with vendors supplying through authorized pharmaceutical wholesalers under multi-year agreements with price-based competition.

Geographic activity centers on Texas and Minnesota, where recent opportunities reflect state-level pharmaceutical procurement infrastructure. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to explore direct-to-manufacturer prescription programs that would affect pharmaceutical sourcing statewide. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products serving participating state and local facilities across multiple states including Oregon; awarded vendors begin contract performance July 1, 2026, with a two-year initial term. Collin County Community Supervision and Corrections Department in Texas posted RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services due July 23, 2026, with an estimated contract value of $600,000 and performance beginning September 1, 2026. Darifenacin procurement opportunities under this code remain embedded within larger pharmaceutical supply aggregations rather than appearing as isolated, single-product solicitations.